Adma Biologics Inc(ADMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 13.33 | EPS (ttm) | 0.7 | Insider Own | 4.16% | Shs Outstand | 225.4M | Perf Week | -1.26% |
| Market Cap | 2.10B | Forward P/E | 9.95 | EPS next Y | 18.41% | Insider Trans | - | Shs Float | 214.7M | Perf Month | -5.2% |
| Enterprise Value | 2.17B | PEG | 0.45 | EPS next Q | 0.2 | Inst Own | 90.12% | Short Float | 10.57% | Perf Quarter | 10.73% |
| Income | 0.17B | P/S | 4.11 | EPS this Y | 21.3% | Inst Trans | -3.77% | Short Ratio | 8.22 | Perf Half Y | -40.08% |
| Sales | 0.51B | P/B | 5.18 | EPS next 5Y | 22.25% | ROA | 27.19% | Short Interest | 22.68M | Perf YTD | -48.52% |
| Book/sh | 1.81 | P/C | 15.46 | EPS past 3/5Y | - | ROE | 41.9% | 52W High | -54.1% ($20.46) | Perf Year | -40.42% |
| Cash/sh | 0.61 | P/FCF | 18.06 | Sales past 3/5Y | 49.05% 64.6% | ROIC | 27.83% | 52W Low | 30.23% ($7.21) | Perf 3Y | 144.53% |
| Dividend Est. | - | EV/EBITDA | 9.68 | EPS Y/Y TTM | -18.53% | Gross Margin | 64.67% | Volatility(W/M) | 2.61% 2.91% | Perf 5Y | 689.08% |
| Dividend TTM | - | EV/Sales | 4.24 | Sales Y/Y TTM | 8.04% | Oper. Margin | 42.26% | ATR (14) | 0.28 | Perf 10Y | 65.9% |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | EPS Q/Q | 19.33% | Profit Margin | 32.98% | RSI (14) | 49.07 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.97 | Sales Q/Q | 1.98% | SMA20 | -1.64% ($9.55) | Beta | 0.7 | Target Price | $18.67 |
| Payout | - | Debt/Eq | 0.5 | Earnings | 2026/8/5 | SMA50 | 2.02% ($9.2) | Rel Volume | 1.03 | Prev Close | $9.45 |
| Employees | 647 | LT Debt/Eq | 0.49 | EPS/Sales Surpr. | 0.98% -0.76% | SMA200 | -25.14% ($12.54) | Avg Volume(3M) | 2.76M | Price | $9.39 |
| IPO | 2013/10/17 | Option/Short | Yes/Yes | Trades | 17402 | Volume | 2,830,948 | Change | -0.63% |
Company
ADMA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩸 This is a U.S. biotech company that develops and manufactures plasma-derived immunoglobulin therapies. It produces immunoglobulin treatments for patients with immune deficiencies and other conditions, and operates its own plasma collection centers to secure source plasma, giving it a vertically integrated business structure. The company is an established, commercial-stage plasma biologics player that has integrated the full process from plasma collection through to immunoglobulin manufacturing.
Over the past 1 year, on the lower side
54% below its 1-year high.
ADMA makes money exceptionally well
42.26% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.3% this year.
Tap to view numbers
The price looks about right
Trading at 13.3 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +144.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 90.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.02%
TMFS 0.01%
PSCH 0.01%
DBSC 0.01%
FFOX 0.01%It ranks #4 in the industry
Based on market cap of $2B.
ADMA $2B PER 13.3
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ADMA?
ADMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADMA?
The market cap of ADMA is approximately $2.1B, ranking 2,050 within its sector.
What is the P/E ratio of ADMA?
ADMA has a P/E ratio of approximately 13.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ADMA?
ADMA has recorded a 52-week high of $20.46 and a low of $7.21.
